DDInter1294 DDInter1840
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Nilutamide {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Nilutamide {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Nilutamide {u} (Compound) resembles {v} (Compound) Flutamide
Flutamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Nilutamide {u} (Compound) resembles {v} (Compound) Nitisinone
Nitisinone {u} (Compound) causes {v} (Side Effect) Haemoglobin
Haemoglobin {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Nilutamide {u} (Compound) treats {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is associated with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Nilutamide {u} (Compound) binds {v} (Gene) POR
POR {u} (Gene) interacts with {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Nilutamide {u} (Compound) binds {v} (Gene) AR
AR {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Nilutamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Nilutamide (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Nilutamide (Compound) resembles Flutamide (Compound) and Flutamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Nilutamide (Compound) resembles Nitisinone (Compound) and Nitisinone (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Trabectedin (Compound)
Nilutamide (Compound) treats prostate cancer (Disease) and prostate cancer (Disease) is associated with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Nilutamide (Compound) binds POR (Gene) and POR (Gene) interacts with CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Trabectedin (Compound)
Nilutamide (Compound) binds AR (Gene) and AR (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)